Andrew Portuguese, MD, on Multiple Myeloma: Real-World Outcomes With Elranatamab

December 15, 2025 By The ASCO Post Staff

Andrew Portuguese, MD, of Fred Hutchinson Cancer Center, discusses findings from a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium looking at the real-world safety and efficacy of the BCMA-CD3 bispecific antibody elranatamab (Abstract 136).  

Related Content